Kuwait Pharmaceuticals & Healthcare Report Q4 2014 - New Market Research Report

From: Fast Market Research, Inc.
Published: Wed Nov 19 2014

Notwithstanding a recent escalation in political uncertainty, Kuwait's healthcare sector is forecast to preserve its trajectory of modest growth through out the remainder of 2014. Rising sales are underpinned by an expanding population, whose levels of chronic conditions increasingly call for the supply of long-term treatments and cutting-edge medical equipment. In addition , apprehension towards fake generics and an accompanying government crackdown ha ve further solidified popular demand for branded drugs. However, a confusing bureaucracy and sluggish implementation of key f oreign d irect i nvestment and i ntellectual p roperty reform will continue to dampen overall investment and restrain Kuwait from matching the pace of other emerging economies.

Headline Expenditure Projections

* Pharmaceuticals: KWD290mn (USD1.02bn) in 2013 to KWD306mn (USD1.10bn) in 2014; +5.6% in local currency terms and +7.6% in US dollar terms. Forecast unchanged from Q3 2014.
* Healthcare: KWD1.43bn (USD5.03bn) in 2013 to KWD1.56bn (USD5.58bn) in 2014; +8.8% in local currency terms and +10.8% in US dollar terms. Forecast unchanged from Q3 2014.

Full Report Details at
- http://www.fastmr.com/prod/900728_kuwait_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=301

Risk/Reward Rating

Kuwait scores 58.5 in BMI's Pharmaceutical Risk/Reward Rating (RRR) for Q414 - unchanged from Q2 and Q3 2014. Kuwait remains in second place, behind Saudi Arabia, out of a total of 31 markets in the region.

Key Trends a nd Developments

In September 2014 Kuwait's government adopted a plan under which it slashed daily allowances offered to patients and their companions for treatments abroad. This is the most recent part of ongoing government initiatives to improve the quality of local healthcare infrastructure and reduce the need to send patients overseas for treatment. More of these measures, with corresponding additional local investment, are likely in the near term.

In September 2014 Kuwait's health ministry entered a four-year contract with Sayyed Hameed Behbehani and Sons Co. to design,...

The Kuwait Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Kuwait Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Kuwaiti pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Kuwait to test other views - a key input for successful budgeting and strategic business planning in the Kuwaiti pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Greece Pharmaceuticals & Healthcare Report Q4 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2014
- Bulgaria Pharmaceuticals & Healthcare Report Q4 2014
Company: Fast Market Research, Inc.
Contact Name: fastmrcom
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »